Elanco Animal Health: 3 Key Takeaways for Long-Term Investors

Elanco Animal Health reported Q3 2026 revenue growth of 11% year-over-year to $1.265 billion, driven by strong pricing power on proprietary products and innovation. The company reduced gross debt by $216 million, achieving sub-3.0x net leverage ahead of schedule, and is targeting $200-250 million in EBITDA savings through its Elanco Ascend efficiency program by 2030. Management maintains pricing discipline without aggressive discounting while expanding market share in high-value treatment categories.